HRMYNGMHealthcare·Biotechnology#116 in industry

Harmony Biosciences Holdings, Inc.

Reports in 10d· 2026-05-07

-17.5% · 90d

$31.10

+0.30 (+0.96%)

News

(2)

April 2026

Apr 3, 20263 weeks agoARSHealthcare

Harmony Biosciences Holdings, Inc. — ARS Filing

HRMYHarmony Biosciences Holdings, Inc.

# 📄 What This Document Is This is Harmony Biosciences' **Annual Report to Shareholders (ARS)**. Think of it as the company's official "year-in-review" magazine sent to its owners. It's a comprehensive summary that blends important financial numbers with business highlights and strategy. Its main j

Read summaryView on SEC EDGAR

Apr 3, 20263 weeks agoDEF 14AHealthcare

Harmony Biosciences Holdings, Inc. — DEF 14A Filing

HRMYHarmony Biosciences Holdings, Inc.

# 🧾 What This Document Is — Your Invitation to the Company's Big Meeting This is a **proxy statement** (Form DEF 14A) for **Harmony Biosciences Holdings, Inc. (HRMY)**. Think of it as the official guidebook and ballot for the company's annual shareholder meeting. The purpose is to give shareholders

Read summaryView on SEC EDGAR

Key Data

Market Cap$1.80B

Open$30.65

Prev Close$30.80

Day Range$30.45 – $31.72

52W Range$25.52 – $40.87

Volume321,660

P/E (TTM)11.47

EPS$2.71

Dividend Yield—

Beta0.89

Profit Margin18.27%

Revenue Growth21.10%

Price Target$43.00(+38.3%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Buy11 analysts

Buy 6Hold 4Sell 1

About

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Healthcare · Biotechnology

293 employees

www.harmonybiosciences.com